Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders

CNS Neuroscience and Therapeutics

Volumn 16, Issue 3, 2010, Pages

  Fernández Ruiz, Javier ^a   Hernández, Mariluz ^a   Ramos, José A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoid dopamine; Drug addiction; Movement disorders Parkinson's disease; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; DOPAMINE; ENDOCANNABINOID; LEVODOPA; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 AGONIST; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR AGONIST; CANNABINOID;

ANTIOXIDANT ACTIVITY; BASAL GANGLION; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; DECARBOXYLATION; DENDRITE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG DEPENDENCE; DYSKINESIA; GLOBUS PALLIDUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; WORKING MEMORY; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODEL; DRUG EFFECTS; LIMBIC SYSTEM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM DISEASES; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; LIMBIC SYSTEM; SIGNAL TRANSDUCTION;

EID: 77952170829     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00144.x     Document Type: Review

References (204)

1. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009 71 : 283 306.
2. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry 2009 21 : 113 121.
3. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009 89 : 309 380.
4. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res 2009 60 : 85 92.
5. Randall MD. Endocannabinoids and the haematological system. Br J Pharmacol 2007 152 : 671 675.
6. Maccarrone M. Endocannabinoids and reproductive endocrinology. Curr Opin Investig Drugs 2009 10 : 305 310.
7. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007 18 : 27 37.
8. Gerdeman GL, Fernández-Ruiz J. The endocannabinoid system in the physiology and pathophysiology of the basal ganglia. I n : Kofalvi A, editor. Cannabinoids and the brain.
9. Fernández-Ruiz J, González S. Cannabinoid control of motor function at the basal ganglia. In : Pertwee RG editor. Handbook of experimental pharmacology - 168 - cannabinoids.
10. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009 156 : 1029 1040.
11. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009 8 : 403 421.
12. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008 154 : 369 383.
13. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. In : Pertwee RG, editor. Handbook of experimental pharmacology - 168 - cannabinoids.
14. Kirkham TC. Cannabinoids and appetite: Food craving and food pleasure. Int Rev Psychiatry 2009 21 : 163 171.
15. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007 7 : 575 582.
16. Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000 23 : 14 20.
17. Ramos JA, Gómez M, de Miguel R. Effects on development. In : Pertwee RG, editor. Handbook of experimental pharmacology - 168 cannabinoids.
18. Pertwee RG. Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond. Addict Biol 2008 13 : 147 159.
19. Pertwee RG. CB1 and CB2 receptor pharmacology. In : Kofalvi A, editor. Cannabinoids and the brain. Springer-Verlag, 2008 91 100.
20. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007 9 : 413 430.
21. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernández-Ruiz JJ, Di Marzo V. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function. Biochem Biophys Res Comm 1999 256 : 377 380.
22. Kunos G, Bátkai S. Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem Res 2001 26 : 1015 1021.
23. Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009 11 : 39 44.
24. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. In : Pertwee RG, editor. Handbook of experimental pharmacology - 168 cannabinoids.
25. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov 2008 7 : 438 455.
26. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003 83 : 1017 1066.
27. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001 22 : 565 572.
28. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008 184 : 435 477.
29. Vinod KY, Hungund BL. Cannabinoid-1 receptor: A novel target for the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2006 10 : 203 210.
30. Wenger T, Moldrich G, Furst S. Neuromorphological background of cannabis addiction. Brain Res Bull 2003 61 : 125 128.
31. Hernández ML, Berrendero F, Suarez I, et al. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Res 2000 857 : 56 65.
32. Van Der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. Eur J Pharmacol 2003 480 : 133 150.
33. Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Implications for schizophrenia and addiction. Cell Mol Life Sci 2006 63 : 1597 1613.
34. Herkenham M, Lynn AB, Little MD, Melvin LS, Johnson MR, de Costa DR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991 11 : 563 583.
35. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992 48 : 655 668.
36. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998 83 : 393 411.
37. Seutin V. Dopaminergic neurones: Much more than dopamine? Br J Pharmacol 2005 146 : 167 169.
38. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007 114 : 13 33.
39. Mezey E, Toth ZE, Cortright DN, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000 97 : 3655 3660.
40. Tzavara ET, Li DL, Moutsimilli L, et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: Therapeutic implications. Biol Psychiatry 2006 59 : 508 515.
41. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V. Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiol Dis 2009 36 : 70 80.
42. Hu SS, Bradshaw HB, Benton VM, et al. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids 2009 81 : 291 301.
43. Bobrov MY, Lizhin AA, Andrianova EL, Gretskaya NM, Frumkina LE, Khaspekov LG, Bezuglov VV. Antioxidant and neuroprotective properties of N-arachidonoyldopamine. Neurosci Lett 2008 431 : 6 11.
44. Oz M, Jaligam V, Galadari S, Petroianu G, Shuba YM, Shippenberg TS. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem 2010 112 : 1454 1464.
45. Wenger T, Moldrich G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 2002 66 : 301 307.
46. Costanzi M, Battaglia M, Rossi-Arnaud C, Cestari V, Castellano C. Effects of anandamide and morphine combinations on memory consolidation in cd1 mice: Involvement of dopaminergic mechanisms. Neurobiol Learn Mem 2004 81 : 144 149.
47. Nasehi M, Sahebgharani M, Haeri-Rohani A, Zarrindast MR. Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats. Neurobiol Learn Mem 2009 92 : 391 399.
48. Murillo-Rodríguez E, Vázquez E, Millán-Aldaco D, Palomero-Rivero M, Drucker-Colin R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur J Pharmacol 2007 562 : 82 91.
49. Yazulla S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog Retin Eye Res 2008 27 : 501 526.
50. Stefano GB, Salzet B, Rialas CM, et al. Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res 1997 763 : 63 68.
51. Smith Y, Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: An overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord 2008 23 : S534 S547.
52. Obeso JA, Marin C, Rodriguez-Oroz C, et al. The basal ganglia in Parkinson's disease: Current concepts and unexplained observations. Ann Neurol 2008 64 : S30 S46.
53. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991 547 267 264.
54. Fusco FR, Martorana A, Giampa C, et al. Immunolocalization of CB1 receptor in rat striatal neurons: A confocal microscopy study. Synapse 2004 53 : 159 167.
55. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 2007 27 : 3663 3676.
56. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurosci 2005 25 : 2874 2884.
57. Lau T, Schloss P. The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons. Eur J Pharmacol 2008 578 : 137 141.
58. Moss DE, McMaster SB, Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 1981 15 : 779 783.
59. Anderson JJ, Kask AM, Chase TN. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. Eur J Pharmacol 1996 295 : 163 168.
60. Marcellino D, Carriba P, Filip M, et al. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 2008 54 : 815 823.
61. 9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 1999 365 : 133 142.
62. Marinelli S, Di Marzo V, Florenzano F, et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 2007 32 : 298 308.
63. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-Ruiz JJ. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 2001 420 : 123 131.
64. de Lago E, de Miguel, Lastres-Becker I, Ramos JA, Fernández-Ruiz JJ. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence. Brain Res 2004 1007 : 152 159.
65. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, Mercuri NB. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 2003 23 : 3136 3344.
66. Lastres-Becker I, Hansen HH, Berrendero F, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 2002 44 : 23 35.
67. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz JJ. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 2003 84 : 1097 1109.
68. Ferreira SG, Lomaglio T, Avelino A, Cruz F, Oliveira CR, Cunha RA, Köfalvi A. N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology 2009 56 : 676 683.
69. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002 109 : 451 460.
70. Martín AB, Fernandez-Espejo E, Ferrer B, et al. Expression and function of CB1 receptor in the rat striatum: Localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008 33 : 1667 1679.
71. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999 2 : 358 363.
72. Meschler JP, Howlett AC. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001 40 : 918 926.
73. Ferré S, Goldberg SR, Lluis C, Franco R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 2009 56 : 226 234.
74. Andersson M, Usiello A, Borgkvist A, et al. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 2005 25 : 8432 8438.
75. Gonzalez B, Paz F, Florán L, Aceves J, Erlij D, Florán B. Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when Gi protein-receptor coupling is restricted: Role of dopamine D2 receptors. J Pharmacol Exp Ther 2009 328 : 822 828.
76. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007 445 : 643 647.
77. Pan B, Hillard CJ, Liu QS. D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. J Neurosci 2008 28 : 14018 14030.
78. Mailleux P, Vanderhaeghen JJ. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study. J Neurochem 1993 61 : 1705 1712. (Pubitemid 23317193)
79. Gubellini P, Picconi B, Bari M, et al. Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J Neurosci 2002 22 : 6900 6907.
80. Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B-Y, Jenner P, Ramos JA, Fernández-Ruiz J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001 14 : 1827 1832.
81. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000 14 : 1432 1438.
82. García-Arencibia M, García C, Fernández-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets 2009 8 : 432 439.
83. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 2001 57 : 2108 2111.
84. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002 17 : 145 149.
85. 9- tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry 2002 35 : 57 61.
86. 9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry 2003 64 : 459 465.
87. Mesnage V, Houeto JL, Bonnet AM, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease. Clin Neuropharmacol 2004 27 : 108 110.
88. Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990 53 : 436 436.
89. Pazos MR, Sagredo O, Fernández-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008 14 : 2317 2325.
90. Müller-Vahl KR. Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother 2003 4 : 1717 1725.
91. 9- tetrahydrocannabinol improves motor control in a patient with musician's dystonia. Mov Disord 2004 19 : 990 991.
92. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007 22 : 1379 1389.
93. Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003 3 : 54 61.
94. Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999 65 : 703 713.
95. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 2003 18 : 1607 1614.
96. Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors. Exp Neurol 2007 208 : 110 119.
97. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology 2004 63 : 1245 1250.
98. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 2005 19 : 96 107.
99. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007 1134 : 162 170.
100. Venderová K, Ruzicka E, Vorísek V, Visnovský P. Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. Mov Disord 2004 19 : 1102 1106.
101. Price DA, Martinez AA, Seillier A, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 2009 29 : 2177 2186.
102. Pérez-Rial S, García-Gutiérrez MS, Molina JA, et al. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging 2009 in press.
103. Fernández-Espejo E, Caraballo I, de Fonseca FR, El Banoua F, Ferrer B, Flores JA, Galan-Rodriguez B. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 2005 18 : 591 601.
104. González S, Scorticati C, Garcia-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 2006 1073-1074 : 209 219.
105. Kelsey JE, Harris O, Cassin J. The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav Brain Res 2009 203 : 304 307.
106. Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 2001 156 : 79 85.
107. Cao X, Liang L, Hadcock JR, et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 2007 323 : 318 326.
108. García-Arencibia M, Ferraro L, Tanganelli S, Fernández-Ruiz J. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 2008 438 : 10 13.
109. García-Arencibia M, García C, Kurz A, et al. Cannabinoid CB1 receptors are early down-regulated followed by a further up-regulation in the basal ganglia of mice with deletion of specific park genes. J Neural Transm Suppl 2009 73 : 269 275.
110. Pisani A, Fezza F, Galati S, et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 2005 57 : 777 7779.
111. Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003 85 : 1018 1025.
112. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002 67 : 53 83.
113. Wise RA. Dopamine and reward: The anhedonia hypothesis 30 years on. Neurotox Res 2008 14 : 169 183.
114. Pierce RC, Kumaresan V. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006 30 : 215 238.
115. Gardner EL. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol Biochem Behav 2005 81 : 263 284.
116. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008 286 : S97 S107.
117. Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998 10 : 2825 2830.
118. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997 276 : 2048 2050.
119. Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Nat Acad Sci USA 1998 95 : 10269 10273.
120. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004 143 : 227 234.
121. Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 2005 48 : 1105 1116.
122. Cheer JF, Kendall DA, Mason R, Marsden CA. Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. Neuropharmacology 2003 44 : 633 641.
123. Pistis M, Porcu G, Melis M, Diana M, Gessa GL. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 2001 14 : 96 102.
124. Pistis M, Muntoni AL, Pillolla G, Gessa GL. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: An in vivo electrophysiological study. Eur J Neurosci 2002 15 : 1795 1802.
125. Massi L, Elezgarai I, Puente N, Reguero L, Grandes P, Manzoni OJ, Georges F. Cannabinoid receptors in the bed nucleus of the stria terminalis control cortical excitation of midbrain dopamine cells in vivo. J Neurosci 2008 28 : 10496 10508.
126. Iversen L. Cannabis and the brain. Brain 2003 126 : 1252 1270.
127. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008 34 : 1111 11121.
128. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008 7 : 68 71.
129. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007 78 : 289 326.
130. González S, Cebeira M, Fernández-Ruiz J. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacol Biochem Behav 2005 81 : 300 318.
131. Parolaro D, Rubino T. The role of the endogenous cannabinoid system in drug addiction. Drug News Perspect 2008 21 : 149 157.
132. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006 29 : 225 232.
133. González S, Fernández-Ruiz JJ, Sparpaglione V, Parolaro D, Ramos JA. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels. Drug Alcoh Depend 2002 66 : 77 84.
134. González S, Schmid PC, Fernández-Ruiz JJ, Krebsbach R, Schmid HHO, Ramos JA. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict Biol 2003 8 : 159 166.
135. Vigano D, Cascio MG, Rubino T, Fezza F, Vaccani A, Di Marzo V, Parolaro D. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacol 2003 28 : 1160 1167.
136. González S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002 954 : 73 81.
137. Basavarajappa BS, Hungund BL. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: An overview. Prostag Leukot Essent Fatty Acids 2002 66 : 287 299.
138. Rubio M, Fernández-Ruiz J, de Miguel R, Maestro B, Michael Walker J, Ramos JA. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Neuropharmacology 2008 54 : 976 988.
139. Rubio M, McHugh D, Fernández-Ruiz J, Bradshaw H, Walker JM. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci Lett 2007 421 : 270 274.
140. Fernández-Ruiz J, de Miguel R, Hernández ML, Cebeira M, Ramos JA. Endocannabinoids and dopamine-related functions in the CNS. In : Onaivi ES, Sugiura T, Di Marzo V, editors. Endocannabinoids: The brain and body's marijuana and beyond.
141. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003 84 : 698 704.
142. Mascia MS, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A, Fratta W. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB1 receptor knockout mice. Eur J Pharmacol 1999 383 : R1 R2.
143. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001 118 : 61 65.
144. Li X, Hoffman AF, Peng XQ, Lupica CR, Gardner EL, Xi ZX. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) 2009 204 : 1 11.
145. Castañé A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002 43 : 857 867.
146. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002 13 : 451 463.
147. Cheer JF, Wassum KM, Sombers LA, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 2007 27 : 791 795.
148. Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, Pistis M. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 2008 28 : 13985 13994.
149. Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: Insights from preclinical studies. Neurosci Biobehav Rev 2006 30 : 680 695.
150. 9-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: An in vivo microdialysis study. Brain Res 2002 948 : 155 158.
151. 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 1998 246 : 169 172.
152. Verrico CD, Jentsch JD, Roth RH. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 2003 49 : 61 66.
153. Szabo B, Muller T, Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 1999 73 : 1084 1089.
154. Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 2002 15 : 2057 2061.
155. Cheer JF, Marsden CA, Kendall DA, Mason R. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: An in vitro electrophysiological study. Neuroscience 2000 99 : 661 667.
156. Hoffman AF, Lupica CR. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: A comparison with opioids. J Neurophysiol 2001 85 : 72 83.
157. Manzoni OJ, Bockaert J. Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. Eur J Pharmacol 2001 412 : R3 R5.
158. Sperlágh B, Windisch K, Andó RD, Sylvester Vizi E. Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int 2009 54 : 452 457.
159. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 2004 24 : 53 62.
160. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001 21 : 109 116.
161. Ponce G, Hoenicka J, Rubio G, et al. Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 2003 8 : 466 467.
162. Zhang PW, Ishiguro H, Ohtsuki T, et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004 9 : 916 931.
163. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002 99 : 8394 8399.
164. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 2003 168 : 164 169.
165. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 2003 17 : 1723 1726.
166. De Vries TJ, Shaham Y, Homberg JR, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nature Med 2001 7 : 1151 1154.
167. Colombo G, Orrù A, Lai P, et al. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: Preclinical evidence. Mol Neurobiol 2007 36 : 102 112.
168. 9-tetrahydrocannabinol. Eur J Pharmacol 1999 376 : 23 26.
169. Beardsley PM, Thomas BF, McMahon LR. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. Int Rev Psychiatry 2009 21 : 134 142.
170. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005 312 : 875 883.
171. Freedland CS, Sharpe AL, Samson HH, Porrino LJ. Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 2001 25 : 277 282.
172. Serra S, Brunetti G, Pani M, Vacca G, Carai MA, Gessa GL, Colombo G. Blockade by the cannabinoid CB1 receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur J Pharmacol 2002 443 : 95 97.
173. Mas-Nieto M, Pommier B, Tzavara ET, et al. Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001 132 : 1809 1816.
174. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 2003 306 : 93 102.
175. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 2008 54 : 438 444.
176. Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005 81 : 387 395.
177. Xi ZX, Gilbert JG, Peng XQ, Pak AC, Li X, Gardner EL. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: Role of glutamate in the nucleus accumbens. J Neurosci 2006 26 : 8531 8536.
178. Harris DS, Anthenelli RM. Expanding treatment of tobacco dependence. Curr Psychiatry Rep 2005 7 : 344 351.
179. Soyka M, Koller G, Schmidt P, et al. ACTOL Study Investigators. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008 28 : 317 324.
180. Luzi S, Morrison PD, Powell J, di Forti M, Murray RM. What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res 2008 14 : 105 112.
181. Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: Towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008 8 : 1037 1048.
182. Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cognitive disorders: The chicken or the egg? Curr Opin Psychiatry 2007 20 : 228 234.
183. Negrete JC, Gill K. Cannabis and schizophrenia. In : Nahas GG, Sutin KM, Harvey DJ, Agurell S, editors. Marihuana and medicine.
184. Knudsen P, Vilmar T. Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr Scand 1984 69 : 162 174.
185. Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): Association study using a single-base polymorphism in coding exon 1. Am J Med Genet 2001 105 : 749 752.
186. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002 7 : 515 518.
187. Martínez-Gras I, Hoenicka J, Ponce G, et al. (AAT)n repeat in the cannabinoid receptor gene, CNR1: Association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 2006 256 : 437 441.
188. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: An in-vivo SPECT study. Psychiatry Res 2001 107 : 173 177.
189. 9- tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009 34 : 759 766.
190. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 2009 48 : 186 190.
191. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006 39 : 421 429.
192. Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, Spano P. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 2007 32 : 2098 2107.
193. Tzavara ET, Degroot A, Wade MR, Davis RJ, Nomikos GG. CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: Role of mGlu5 receptors. Eur Neuropsychopharmacol 2009 19 : 196 204.
194. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999 10 : 1665 1669.
195. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004 29 : 2108 2114.
196. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003 2 : 5.
197. 3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001 103 : 9 15.
198. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004 28 : 355 360.
199. Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006 172 : 556 560.
200. Berding G, Schneider U, Gielow P, et al. Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. Psychiatry Res 2006 147 : 249 256.
201. Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, Weis S. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007 114 : 1055 1063.
202. Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008 65 : 772 784.
203. Tzavara ET, Davis RJ, Perry KW, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for therapeutic actions. Br J Pharmacol 2003 138 : 544 553.
204. Meltzer HY, Arvanitis L, Bauer D, Rein W Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004 161 : 975 984.